|
Value of a model combining clinical indicators with qualitative and quantitative contrast-enhanced ultrasound parameters for differentiating benign and malignant prostatic lesions
|
L. Yu   , F. Shen , X. Chen , L. Han , Y. Qiu |
| Department of Ultrasound, Haining Central Hospital, Haining, China , qiuyun94028455@163.com |
|
|
Abstract: (340 Views) |
Background: Benign prostate lesions and cancer can be difficult to separate when the judgment depends on one test only, this study reviewed routine clinical data, visual CEUS signs, and measured CEUS blood-flow values, then combined useful items in a simple prediction model. Materials and Methods: We reviewed 120 patients from one hospital, all had pathological proof of a prostate lesion and underwent transrectal ultrasound plus CEUS between January 2021 and December 2025; clinical indexes, image signs, and curve-based CEUS values were checked in benign and malignant cases, related variables were screened with logistic regression, and ROC analysis together with bootstrap resampling was used for model checking. Results: The malignant cases showed an unfavorable PSA pattern and abnormal DRE more often than benign cases, on CEUS they also had more hyperenhancement, uneven enhancement, early wash-in, and perfusion defects; the curve data suggested quicker and stronger enhancement. In the adjusted analysis, f/tPSA, PSAD, early wash-in, and PI remained related to cancer. The model reached an AUC of 0.930, with sensitivity of 82.2% and specificity of 89.3%; the corrected AUC after bootstrap testing was 0.918. Conclusion: Putting clinical indexes together with visual and numerical CEUS information gave a useful and internally stable way to separate benign prostate lesions from malignant ones. |
|
| Keywords: Prostatic neoplasms, ultrasonography, contrast media, prostate-specific antigen, differential diagnosis. |
|
|
Full-Text [PDF 917 kb]
(74 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Bergengren O, Pekala KR and Matsoukas K, et al. (2023) 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. European Urology, 84(2): 191-206. [ DOI:10.1016/j.eururo.2023.04.021] 2. Chen W, Xu L, Deng H, Zhu Z and Yang D (2025) Role of USP10/METTL3/CXCR4 Axis in Immunotherapy of Castration-Resistant Prostate Cancer. Iran J Allergy Asthma Immunol, 24(3): 334-346. [ DOI:10.18502/ijaai.v24i3.18683] 3. Nayan M, Carvalho FLF and Feldman AS (2022) Active surveillance for intermediate-risk prostate cancer. World Journal of Urology, 40(1): 79-86. [ DOI:10.1007/s00345-021-03893-1] 4. Liu S, Hsu E and Aslan M, et al. (2025) Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis. Cancer Research, 85(23): 4632-4647. [ DOI:10.1158/0008-5472.CAN-24-4855] 5. Carlsson SV and Vickers AJ (2020) Screening for Prostate Cancer. The Medical Clinics of North America, 104(6): 1051-1062. [ DOI:10.1016/j.mcna.2020.08.007] 6. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A and Mashele S (2022) Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 27(17): 5730. [ DOI:10.3390/molecules27175730] 7. Deng R, Liu Y and Wang K, et al. (2024) Comparison of MRI artificial intelligence-guided cognitive fusion-targeted biopsy versus routine cognitive fusion-targeted prostate biopsy in prostate cancer diagnosis: a randomized controlled trial. BMC Medicine, 22(1): 530. [ DOI:10.1186/s12916-024-03742-z] 8. Dunn MW (2017) Prostate Cancer Screening. Seminars in Oncology Nursing, 33(2): 156-164. [ DOI:10.1016/j.soncn.2017.02.003] 9. Merriel SWD, Funston G and Hamilton W (2018) Prostate Cancer in Primary Care. Advances in Therapy, 35(9): 1285-1294. [ DOI:10.1007/s12325-018-0766-1] 10. Leslie SW, Soon-Sutton TL and Skelton WP: Prostate Cancer; StatPearls. Treasure Island (FL), StatPearls Publishing, 2026 11. Zhu Y, Shan J and Zhang Y, et al. (2019) Prostate Cancer Vascularity: Superb Microvascular Imaging Ultrasonography with Histopathology Correlation. Medical Science Monitor, 25: 8571-8578. [ DOI:10.12659/MSM.918318] 12. Merriel SWD, Pocock L and Gilbert E, et al. (2022) Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Medicine, 20(1): 54. [ DOI:10.1186/s12916-021-02230-y] 13. Apfelbeck M, Clevert D, Ricke J, Stief C and Schlenker B (2018) Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Clinical Hemorheology and Microcirculation, 69(1-2): 93-100. [ DOI:10.3233/CH-189123] 14. Dias AB, O'Brien C, Correas J and Ghai S (2022) Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review. The British Journal of Radiology, 95(1131): 20210633. [ DOI:10.1259/bjr.20210633] 15. Gurwin A, Kowalczyk K and Knecht-Gurwin K, et al. (2022) Alternatives for MRI in Prostate Cancer Diagnostics-Review of Current Ultrasound-Based Techniques. Cancers, 14(8): 1859. [ DOI:10.3390/cancers14081859] 16. Chen L, Xu Y and Wang Y, et al. (2024) Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Molecular Cancer, 23(1): 229. [ DOI:10.1186/s12943-024-02137-1] 17. Maxeiner A, Fischer T and Schwabe J, et al. (2019) Contrast-Enhanced Ultrasound (CEUS) and Quantitative Perfusion Analysis in Patients with Suspicion for Prostate Cancer. Ultraschall in Der Medizin (Stuttgart, Germany: 1980), 40(3): 340-348. [ DOI:10.1055/a-0594-2093] 18. Wildeboer RR, Postema AW, Demi L, Kuenen MPJ, Wijkstra H and Mischi M (2017) Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. European Radiology, 27(8): 3226-3234. [ DOI:10.1007/s00330-016-4693-8] 19. Postema AW, Gayet MCW and van Sloun RJG, et al. (2020) Contrast-enhanced ultrasound with dispersion analysis for the localization of prostate cancer: correlation with radical prostatectomy specimens. World Journal of Urology, 38(11): 2811-2818. [ DOI:10.1007/s00345-020-03103-4] 20. Wildeboer RR, Mannaerts CK and van Sloun RJG, et al. (2020) Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics. European Radiology, 30(2): 806-815. [ DOI:10.1007/s00330-019-06436-w] 21. Wildeboer RR, van Sloun RJG, Huang P, Wijkstra H and Mischi M (2019) 3-D multi-parametric contrast-enhanced ultrasound for the prediction of prostate cancer. Ultrasound in Medicine and Biology, 45(10): 2713-2724. [ DOI:10.1016/j.ultrasmedbio.2019.05.017] 22. Wegierak D, Cooley MB and Perera R, et al. (2024) Decorrelation time mapping as an analysis tool for nanobubble-based contrast enhanced ultrasound imaging. IEEE Transactions on Medical Imaging, 43(6): 2370-2380. [ DOI:10.1109/TMI.2024.3364076] 23. Rebello RJ, Oing C and Knudsen KE, et al. (2021) Prostate cancer. Nature Reviews Disease Primers, 7(1): 9. [ DOI:10.1038/s41572-020-00243-0] 24. Guo S, Kang F and Ma S, et al. (2024) The PRIMARY score: Diagnostic performance and added value compared with MRI in detecting clinically significant prostate cancer. Clinical Nuclear Medicine, 49(1): 37-44. [ DOI:10.1097/RLU.0000000000004951] 25. Mei J, Zhao Y, Jiang Y, Wang J and Yu J (2020) Association between contrast-enhanced ultrasound indicators and prostate cancer biochemical recurrence after treatment. Cancer Management and Research, 12: 4959-4968. [ DOI:10.2147/CMAR.S250907] 26. Yang F, Guo W, Sun S and Huang Y (2024) Diagnostic value of tripartite magnetic resonance imaging model based on T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging for prostatitis, prostatic hyperplasia and prostate cancer. Int J Radiat Res, 22(1): 111-116. [ DOI:10.61186/ijrr.22.1.111] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Yu L, Shen F, Chen X, Han L, Qiu Y. Value of a model combining clinical indicators with qualitative and quantitative contrast-enhanced ultrasound parameters for differentiating benign and malignant prostatic lesions. Int J Radiat Res 2026; 24 (3) :735-740 URL: http://ijrr.com/article-1-7231-en.html
|
